Alisha H. Bent, M.D.
Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2016 | Meharry Medical College, Nashville, TN, USA, MD, Doctor of Medicine |
| 2012 | University of Florida, Gainesville, FL, USA, BS, Food Science and Nutrition-Pre-Med |
Postgraduate Training
| 2019-2022 | Clinical Fellowship, Hematology/Oncology Fellow, The University of Texas MD Anderson Cancer Center, Houston, TX |
| 2016-2019 | Clinical Residency, Internal Medicine Resident, University of Texas Southwestern Medical Center, Dallas, TX |
Board Certifications
| 2022 | American Board of Medical Oncology |
| 2019 | American Board of Internal Medicine (ABIM) |
Honors & Awards
| 2021 | Holmes-Abrams Fellowship Award, Colorectal Cancer Research |
| 2021 | Chief Fellow, The University of Texas MD Anderson Cancer Center |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Bent A, Raghavan S, Dasari A, Kopetz S. The Future of ctDNA-Defined Minimal Residual Disease: Personalizing Adjuvant Therapy in Colorectal Cancer. Clin Colorectal Cancer 21(2):89-95, 2022. e-Pub 2022.
- Bowman IA, Bent A, Le T, Christie A, Wardak Z, Arriaga Y, Courtney K, Hammers H, Barnett S, Mickey B, Patel T, Whitworth T, Stojadinovic S, Hannan R, Nedzi L, Timmerman R, Brugarolas J. Improved Survival Outcomes for Kidney Cancer Patients With Brain Metastases. Clin Genitourin Cancer 17(2):e263-e272, 2019. e-Pub 2018. PMID: 30538068.
- Buran TJ, Sandhu AK, Azeredo AM, Bent AH, Williamson JG, Gu L. Effects of exogenous abscisic acid on fruit quality, antioxidant capacities, and phytochemical contents of southern high bush blueberries. Food Chem 132(3):1375-1381, 2012. e-Pub 2011. PMID: 29243625.
Other Articles
- Bent, A & Kopetz, S Going with the Flow: The Promise of Plasma-Only Circulating Tumor DNA Assays. Clinical Cancer Research 27(20), 2021.
Abstracts
- Arvind Dasari, Alisha Bent, Kristin Alfaro-Munoz, Ryan Huey, Benny Johnson, Michael Lee, Maria Pia Morelli, Van Morris, Michael Overman, Christine Parseghian, Kanwal Raghav, John Shen, Jason Willis, Timothy Newhook, Abhineet Uppal, Y. Nancy You, Tsuyoshi Konishi, George Chang, Scott Kopetz, Robert Wolff. Association of positive ctDNA-based minimal residual disease assays during surveillance and undiagnosed concomitant radiographic recurrences in colorectal cancer (CRC): Results from the MD Anderson INTERCEPT program. Journal of Clinical Oncology, 2023.
- Bent, A. H., Maru, D. M., Vauthey, J., Dasari, A., Johnson, B., Kee, B. K., ... & Raghav, K. P. S.. HER3 expression in metastatic colorectal cancer: Defining the clinicomolecular profile of an emerging target. Journal of Clinical Oncology, 2022.
- Bowman, A., Bent, A., Le, T., Christie, A., Wardak, Z., Bruce Mickey, S., Timmerman, R., Hannan, R., Brugarolas, J.. Improved survival rates in kidney cancer patients with brain metastases treated with modern multidisciplinary approaches. Journal of Clinical Oncology, 2018.
- Bosse, D., Xie, W., Wells, C., Lalani, A., Donskov, F., Bent AH., Sim, H., Beuselinck, B., Bamias, A., Porta, C., Vaishampayan, U., Pal, S., Agarwal, N., Srinivas, S., Rini, B., Alva, A., Wood, L., Kapoor, A., Choueiri, T., Chin Heng, D.. Clinical outcomes according to ethnicity in patients with metastatic renal cell carcinoma (mRCC) treated with VEGF-targeted therapy (TT). Journal of Clinical Oncology, 2017.
Book Chapters
- Parseghian, C., Bent, A. Colorectal Liver Metastases. In: Targeted Therapy Beyond EGFR and VEGF. Spring Nature, 2021.
Grant & Contract Support
| Title: | DAILY: Vitamin D, Aspirin, ExercIse, Low Saturated Fat Foods StudY in Colorectal Cancer Patients with Minimal Residual Disease |
| Funding Source: | UT Md Anderson Cancer Center |
| Role: | Co-Principal Investigator |
| Title: | Phase 2, Randomized, Open-label Study of Onvansertib in Combination with FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Patients with a KRAS or NRAS Mutation |
| Funding Source: | Cardiff Oncology |
| Role: | Principal Investigator |